Neumora Therapeutics (NMRA) Current Leases (2022 - 2026)

Neumora Therapeutics' Current Leases history runs 5 years deep, the most recent figure standing at $291000.0 for Q1 2026.

• In Q1 2026, Current Leases fell 68.98% year-over-year to $291000.0; the TTM figure through Mar 2026 stood at $291000.0 (down 68.98% YoY), while the FY2025 annual figure was $284000.0, down 84.67% from the prior year.
• Current Leases for Q1 2026 stood at $291000.0, up from $284000.0 in the prior quarter.
• The five-year high for Current Leases was $3.6 million in Q2 2024, with the low at $171000.0 in Q2 2025.
• The 5-year median for Current Leases is $2.3 million (2024), against an average of $2.0 million.
• The sharpest annual moves came in 2023 and 2025: Current Leases increased 0.24% in 2023, then tumbled 95.26% in 2025.
• Neumora Therapeutics' Current Leases stood at $3.4 million in 2022, then climbed by 0.24% to $3.4 million in 2023, then plunged by 45.15% to $1.9 million in 2024, then plunged by 84.67% to $284000.0 in 2025, then grew by 2.46% to $291000.0 in 2026.
• Business Quant data shows NMRA's Current Leases at $291000.0 in Q1 2026, $284000.0 in Q4 2025, and $256000.0 in Q3 2025.